Literature DB >> 28420318

Advancing Clinicopathologic Diagnosis of High-risk Neuroblastoma Using Computerized Image Analysis and Proteomic Profiling.

M Khalid Khan Niazi1, Jonathan H Chung2, Katherine J Heaton-Johnson3, Daniel Martinez4, Raquel Castellanos5, Meredith S Irwin6, Stephen R Master7, Bruce R Pawel3,4, Metin N Gurcan1, Daniel A Weiser2,5.   

Abstract

A subset of patients with neuroblastoma are at extremely high risk for treatment failure, though they are not identifiable at diagnosis and therefore have the highest mortality with conventional treatment approaches. Despite tremendous understanding of clinical and biological features that correlate with prognosis, neuroblastoma at ultra-high risk for treatment failure remains a diagnostic challenge. As a first step towards improving prognostic risk stratification within the high-risk group of patients, we determined the feasibility of using computerized image analysis and proteomic profiling on single slides from diagnostic tissue specimens. After expert pathologist review of tumor sections to ensure quality and representative material input, we evaluated multiple regions of single slides as well as multiple sections from different patients' tumors using computational histologic analysis and semiquantitative proteomic profiling. We found that both approaches determined that intertumor heterogeneity was greater than intratumor heterogeneity. Unbiased clustering of samples was greatest within a tumor, suggesting a single section can be representative of the tumor as a whole. There is expected heterogeneity between tumor samples from different individuals with a high degree of similarity among specimens derived from the same patient. Both techniques are novel to supplement pathologist review of neuroblastoma for refined risk stratification, particularly since we demonstrate these results using only a single slide derived from what is usually a scarce tissue resource. Due to limitations of traditional approaches for upfront stratification, integration of new modalities with data derived from one section of tumor hold promise as tools to improve outcomes.

Entities:  

Keywords:  image analysis; neuroblastoma; prognostic biomarker; proteomics; tumor heterogeneity

Mesh:

Substances:

Year:  2017        PMID: 28420318      PMCID: PMC7059208          DOI: 10.1177/1093526617698603

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  36 in total

1.  Chromosome 1p and 11q deletions and outcome in neuroblastoma.

Authors:  Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

Review 2.  Histopathological image analysis: a review.

Authors:  Metin N Gurcan; Laura E Boucheron; Ali Can; Anant Madabhushi; Nasir M Rajpoot; B Yener
Journal:  IEEE Rev Biomed Eng       Date:  2009-10-30

3.  Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.

Authors:  A T Look; F A Hayes; J J Shuster; E C Douglass; R P Castleberry; L C Bowman; E I Smith; G M Brodeur
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

Review 4.  Histo-proteomic profiling of formalin-fixed, paraffin-embedded tissue.

Authors:  Kant M Matsuda; Joon-Yong Chung; Stephen M Hewitt
Journal:  Expert Rev Proteomics       Date:  2010-04       Impact factor: 3.940

5.  Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.

Authors:  Larry L Wang; Rie Suganuma; Naohiko Ikegaki; Xao Tang; Arlene Naranjo; Patrick McGrady; Wendy B London; Michael D Hogarty; Julie M Gastier-Foster; A Thomas Look; Julie R Park; John M Maris; Susan L Cohn; Robert C Seeger; Hiroyuki Shimada
Journal:  Cancer       Date:  2013-07-30       Impact factor: 6.860

Review 6.  Perinatal neuroblastoma.

Authors:  Jed G Nuchtern
Journal:  Semin Pediatr Surg       Date:  2006-02       Impact factor: 2.754

7.  ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Authors:  Scott C Bresler; Daniel A Weiser; Peter J Huwe; Jin H Park; Kateryna Krytska; Hannah Ryles; Marci Laudenslager; Eric F Rappaport; Andrew C Wood; Patrick W McGrady; Michael D Hogarty; Wendy B London; Ravi Radhakrishnan; Mark A Lemmon; Yaël P Mossé
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

8.  Heterogeneity of the MYCN oncogene in neuroblastoma.

Authors:  Jessica Theissen; Marc Boensch; Ruediger Spitz; David Betts; Sabine Stegmaier; Holger Christiansen; Felix Niggli; Freimut Schilling; Manfred Schwab; Thorsten Simon; Frank Westermann; Frank Berthold; Barbara Hero
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 9.  Complete solubilization of formalin-fixed, paraffin-embedded tissue may improve proteomic studies.

Authors:  Shan-Rong Shi; Clive R Taylor; Carol B Fowler; Jeffrey T Mason
Journal:  Proteomics Clin Appl       Date:  2013-03-06       Impact factor: 3.494

Review 10.  Proteomic approaches in neuroblastoma: a complementary clinical platform for the future.

Authors:  Hari R Kumar; Xiaoling Zhong; Frederick J Rescorla; Robert J Hickey; Linda H Malkas; John A Sandoval
Journal:  Expert Rev Proteomics       Date:  2009-08       Impact factor: 3.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.